Track VOR and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Vor Biopharma Inc
500 Boylston Street, Boston, MA, United States, 02116
IPO
2021
Employees
76
Industry
Biotechnology
Sector
Healthcare
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 202611-11
0
Q4 20259-9
0
2-quarter cumulative
20 sells0 buys
Analyst Ratings
5 analysts covering
Hold100%recommend hold
Buy
0
Hold
5
Sell
0